|Bid||70.71 x 600|
|Ask||70.79 x 200|
|Day's Range||70.64 - 71.90|
|52 Week Range||63.76 - 88.85|
|PE Ratio (TTM)||7.47|
|Dividend & Yield||2.08 (2.95%)|
|1y Target Est||N/A|
Sameul Isaly, founder of one of the world’s most well-known healthcare funds, has made two key moves on Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Gilead Sciences Inc (NASDAQ:GILD). Isaly is the managing partner of OrbiMed, a global management firm that has assets under management of over $13 billion. Isaly is closely tracked by investors due to his exceptional track record: at the beginning of 2016, Barron’s said he was the only US mutual fund manager to beat the S&P 500 for an incredible 25 straight years.
Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.